<DOC>
	<DOCNO>NCT02270905</DOCNO>
	<brief_summary>The safety performance dCELL速 Meniscus evaluate 60 patient partial replacement native medial lateral meniscus investigational product .</brief_summary>
	<brief_title>Clinical Evaluation dCELL速 Meniscus Partial Replacement Meniscus</brief_title>
	<detailed_description>The dCELL速 Meniscus novel decellularised porcine xenograft process use patented variation Tissue Regenix 's platform dCELL速 technology render biocompatible free cellular material , leave behind acellular biological scaffold safe human implantation whilst preserve biomechanical property . It indicate biological implant replace part native meniscus knee patient present chronic pain follow fail previous meniscus repair partial meniscectomy .</detailed_description>
	<mesh_term>Knee Injuries</mesh_term>
	<criteria>Patients diagnose chronic pain follow fail previous meniscus repair partial meniscectomy Must stable , well align knee ligament laxity Grade II less Osteoarthritis &lt; grade 3 Kellgren Lawrence scale Patients give write informed consent ; willing able comply entire study procedure include rehabilitation protocol Body Mass Index ( BMI ) great 35 kg/m2 Treatment investigational drug device within two month prior screen Patients present abnormal degenerative osteoarthritis joint Patients current ligament injury require immediate surgery ligament surgery previous three month Patients use anticoagulant Patients current immunosuppressive radiation therapy receive therapy within six month screen Patients diabetes cardiovascular disease precludes elective surgery Patients document renal disease metabolic bone disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>meniscus</keyword>
	<keyword>meniscectomy</keyword>
	<keyword>decellularised</keyword>
	<keyword>xenograft</keyword>
</DOC>